Conditions: Vascular Anomalies; Vascular Anomaly; TIE2/PIK3CA Pathway Driven Vascular Anomalies
Interventions: Drug: alpelisib (BYL719)
Sponsors: Children’s Hospital of Philadelphia; Novartis; CaNVAS (Consortium of Investigators of Vascular Anomalies); Texas Children’s; Arkansas Children’s Hospital Research Institute; Nationwide Children’s Hospital; Nemours Children’s Health; Boston Children’s Hospital; NYU Langone Health; Children’s Healthcare of Atlanta; Oregon Health and Science University; Children’s Hospital Colorado; Riley Children’s Health; Children’s Hospital of Los Angeles (CHLA); Seattle Children’s Hospital; Children’s Hospital of Orange County (CHOC); Children’s Wisconsin – Milwaukee; University of North Carolina; Children’s Hospital Medical Center, Cincinnati; University of California, San Francisco; Columbia University Irving Medical Center, New York, NY; Children’s Hospital of Pittsburg; Dell Children’s Medical Center of Central Texas; Vanderbilt University Medical Center; Helen DeVos Children’s Hospital; Washington University School of Medicine; Lucile Packard Children’s Hospital Stanford
Active, not **RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
